Navigation Links
Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
Date:5/20/2011

HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.  The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.      

The patent represents years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery.  It is the first of many patents that Serina has applied for.  "This patent award validates our invention and design of a novel drug delivery platform and allows Serina the opportunity to advance some of its proprietary ideas towards full development and eventually commercialization," said Dr. Michael D. Bentley, Chief Scientific Officer and cofounder of the company. "We are now in a position to build a strong pipeline of polymer therapeutic molecules."  

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

Media Contact:  Karen Petersen, 256-327-9434


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
3. Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
4. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
5. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
6. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
7. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
8. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
9. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
10. Echo Therapeutics Expands Into New Headquarters in Philadelphia
11. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... 2016 Frontier Pharma: Chronic Obstructive Pulmonary ... Chronic Obstructive Pulmonary Disease (COPD) ... of the airways and lungs. Persistent breathing difficulties ... disease one of the leading causes of morbidity ... world. COPD is linked to cumulative exposure to ...
(Date:2/4/2016)... Medical, Inc. (Nasdaq: AEMD ), the pioneer ... diseases, today announced results for the third quarter ... --> --> "Beyond ... quarterly call, we strategically advanced pre-clinical and clinical ... the Aethlon Hemopurifier® as a leading broad-spectrum countermeasure ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... Looking for a ... be at the tips of your toes. Foot massage, whether administered by a professional ... comfort and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) ...
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today ... for and donate to Give To Cure’s campaign that is crowdfunding clinical trials to ... make and share payments through a smart device. In 2015 alone, Venmo processed $7.5 ...
(Date:2/5/2016)... ... 2016 , ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure ... to individuals in need. The event is scheduled to take place on February 27, ... to provide dental care to community members in need. Each patient will be given ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected ... eating disorders is significant self-criticism, and consequently these patients experience this disease with their ... means for coping with this unease, but also leads to a reservoir of emotions ...
Breaking Medicine News(10 mins):